about
sameAs
Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents.Neurodegeneration and inflammation in hippocampus in experimental autoimmune encephalomyelitis induced in rats by one--time administration of encephalitogenic T cells.Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide.Readiness Visual Analog Scale: A Simple Way to Predict Post-Stroke Smoking BehaviorEstrogen and cytokines production - the possible cause of gender differences in neurological diseases.Pharmacy switch of antipsychotic medications: patient's perspective.Changes in pre-hospital management of vascular risk factors among patients admitted due to recurrent stroke in Poland from 1995 to 2013.Increased Occurrence of Valproic Acid-Induced Hyperammonemia in Carriers of T1405N Polymorphism in Carbamoyl Phosphate Synthetase 1 GeneCarotid intima media thickness and blood biomarkers of atherosclerosis in patients after stroke or myocardial infarction.Inflammation and gliosis in neurological diseases--clinical implications.Application of microRNAs in diagnosis and treatment of cardiovascular disease.Mechanical thrombectomy in acute stroke - Five years of experience in Poland.Ibudilast: a non‑selective phosphodiesterase inhibitor in brain disorders.Matrix Metalloproteinase 9 in Epilepsy: The Role of Neuroinflammation in Seizure DevelopmentThe phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson's disease.Eye of the tiger sign in a 23 year patient with mitochondrial membrane protein associated neurodegeneration.Down-regulation of microglia and NG2-positive cells reaction in trimethyltin-injured hippocampus of rats treated with myelin basic protein-reactive T cells: possible contribution to the neuroprotective effect of T cells.Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice.Post intoxicative therapeutic immunization with myelin oligodendrocyte glycoproteine (MOG 35-55) suppresses spontaneous regeneration of dopaminergic neurons injured with 1-methyl-4 phenyl-1,2,3,6-tetrahydropiridine (MPTP).Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse.Cytokines in the pathogenesis of hemophilic arthropathy.Dopamine, serotonin and noradrenaline changes in the striatum of C57BL mice following myelin oligodendrocyte glycoprotein (MOG) 35-55 and complete Freund adjuvant (CFA) administration.Population-Specific Associations of Deleterious Rare Variants in Coding Region of P2RY1-P2RY12 Purinergic Receptor Genes in Large-Vessel Ischemic Stroke Patients.Valproic acid malabsorption in 30 year-old female patient - Case study.Mechanisms of cardioembolic stroke revisited. Atrial cardiopathy.Measurement of Nutritional Status Using Body Mass Index, Waist-to-Hip Ratio, and Waist Circumference to Predict Treatment Outcome in Females and Males with Acute First-Ever Ischemic Stroke.Intracerebral hemorrhage in the context of cerebral amyloid angiopathy and varied time of onset of cerebral venous thrombosis: a case report.Anti-myelin basic protein T cells protect hippocampal neurons against trimethyltin-induced damage.Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease.Transcranial Sonography in Mitochondrial Membrane Protein-Associated Neurodegeneration.Evolution and novel radiological changes of neurodegeneration associated with mutations in C19orf12.Concomitant heterozygous factor V Leiden mutation and homozygous prothrombin gene variant (G20210A) in patient with cerebral venous thrombosis.Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).Serum metalloproteinase 9 levels increase after generalized tonic-clonic seizures.Noninfectious complications of acute stroke and their impact on hospital mortality in patients admitted to a stroke unit in Warsaw from 1995 to 2015.Novel mutation of the NOTCH3 gene in a Polish family with CADASIL.Embolic strokes of undetermined source in a cohort of Polish stroke patients.Infections Diagnosed after Admission to a Stroke Unit and Their Impact on Hospital Mortality in Poland from 1995 to 2015.Comparison of Plasma, Saliva, and Hair Levetiracetam Concentrations.
P50
Q30360306-84256541-B5CF-4F3B-B114-D024C3518E0DQ30651929-0B50A075-BF89-44CA-A341-05DDAE2B1258Q34775882-416288B1-EDA5-4668-839D-049912F015F3Q36012919-7CD6FA2F-5009-4C1D-B80C-4C9052E366A1Q36074614-99C7AE51-C745-4326-B829-BAFB1EF6533DQ36093400-79F8C550-AF80-4488-9C83-297E595BB46DQ37100539-D4B8C004-7EB7-4C67-8218-41369A3C9B64Q37111229-77F82C57-3AB3-4B7A-8544-A20D1570163BQ37555125-8C9D7031-9A42-4F01-AF44-112526D60CADQ37799890-DC7DA093-97B0-40F6-AA62-4C5EA1F1D158Q38264294-81F130F0-7BEE-497B-873D-68D8D49472A7Q38653640-F16431FB-825A-4A39-AF26-126A821F1286Q38930132-C02D6E37-4F60-4A70-ABD3-7EA93EB33621Q39095751-9799DD00-2FF2-4C10-9856-5C684B6039CFQ41913461-B2B31999-4572-47DE-8FAE-C9B87E2CA511Q42452052-A5283486-3B6A-4E9E-8289-8EA632F9B078Q42474842-A1727BAE-9C55-4C78-B33E-305D29CA38DCQ42627909-584019AA-7B75-46CF-87DF-37FFC5F4AC6DQ44154168-73E0E26C-D9E0-4261-B5A6-7C417E6E5700Q44554399-D56BD00E-613F-45B0-A909-C29E5A06D800Q45015052-6F007974-ABB5-44DF-B8CA-C3BD92375B36Q45874704-74587E11-18C9-4147-A76A-80C4AC7DB29BQ46718260-1729B413-D9E9-4D5B-A4A4-7640F2B5D740Q47302148-653EBF1D-8043-49AF-B3EC-90098D98734BQ47816522-34D8381D-7EC4-4B1F-9349-31C3C077E621Q47972270-AE6CEECE-82F3-4E06-8D16-CF29B6452DE1Q48001555-5B3A3B60-FE9E-4432-925F-7BFEFCB49EF4Q48031519-228DB38F-CD68-4C02-8F92-12621F4ADD77Q48170916-99389F80-95E2-44DE-A697-6C75B82CFDB6Q48223155-D7EEC25E-D8E5-410C-9035-E74E27F8F3E2Q48239923-6BF463A3-5887-4122-94D9-94677AD510A7Q48243121-83F56076-5FDA-46DB-8B4C-683565024861Q48303900-1A307920-C288-468A-B505-D6E5F61BFDF4Q48385796-B722E31B-A34D-439A-B0AF-2D0CC1E9656AQ48417220-1CB9E55C-1B19-43CA-8954-4C05336F4581Q49551470-074CE3C0-0BC7-4E38-88EB-CEB92955F34EQ51665448-DF475F0A-C89E-4600-BB5B-F65E2F5346B9Q52647366-99680F25-74B1-4BE4-B210-98F601C2CC3AQ52662117-0E7B496A-168C-45BC-9DDD-4276F9C0D8A5Q54671924-7614BCE4-8EF5-4853-8C2A-C2D80A491EA2
P50
description
Pools onderzoekster
@nl
researcher ORCID ID = 0000-0001-6553-9080
@en
name
I Kurkowska-Jastrzebska
@es
Iwona Kurkowska-Jastrzębska
@ast
Iwona Kurkowska-Jastrzębska
@ca
Iwona Kurkowska-Jastrzębska
@cs
Iwona Kurkowska-Jastrzębska
@en
Iwona Kurkowska-Jastrzębska
@gl
Iwona Kurkowska-Jastrzębska
@hr
Iwona Kurkowska-Jastrzębska
@hsb
Iwona Kurkowska-Jastrzębska
@it
Iwona Kurkowska-Jastrzębska
@nl
type
label
I Kurkowska-Jastrzebska
@es
Iwona Kurkowska-Jastrzębska
@ast
Iwona Kurkowska-Jastrzębska
@ca
Iwona Kurkowska-Jastrzębska
@cs
Iwona Kurkowska-Jastrzębska
@en
Iwona Kurkowska-Jastrzębska
@gl
Iwona Kurkowska-Jastrzębska
@hr
Iwona Kurkowska-Jastrzębska
@hsb
Iwona Kurkowska-Jastrzębska
@it
Iwona Kurkowska-Jastrzębska
@nl
altLabel
I Kurkowska-Jastrzebska
@ast
I Kurkowska-Jastrzebska
@en
I Kurkowska-Jastrzebska
@nl
Iwona Kurkowska-Jastrzebska
@en
prefLabel
I Kurkowska-Jastrzebska
@es
Iwona Kurkowska-Jastrzębska
@ast
Iwona Kurkowska-Jastrzębska
@ca
Iwona Kurkowska-Jastrzębska
@cs
Iwona Kurkowska-Jastrzębska
@en
Iwona Kurkowska-Jastrzębska
@gl
Iwona Kurkowska-Jastrzębska
@hr
Iwona Kurkowska-Jastrzębska
@hsb
Iwona Kurkowska-Jastrzębska
@it
Iwona Kurkowska-Jastrzębska
@nl
P214
P106
P1153
6603471195
P1412
P1559
Iwona Kurkowska-Jastrzębska
@pl
P21
P214
P27
P31
P3124
P496
0000-0001-6553-9080
P735
P7859
viaf-102011693